Jorveza is a medicine used to treat adults and children from the age of two years with eosinophilic oesophagitis. Eosinophilic oesophagitis is inflammation of the oesophagus (the passage that leads from the mouth to the stomach), which causes symptoms such as dysphagia (difficulty swallowing) and blockage of the oesophagus. It is caused by a large build-up of white blood cells called eosinophils in the lining of the oesophagus. Eosinophilic oesophagitis is rare, and Jorveza was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 5 August 2013. Jorveza contains the active substance budesonide.
Therapeutic Indication
### Therapeutic indication Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Jorveza 0.2 mg/mL oral suspension is indicated for the treatment of eosinophilic esophagitis (EoE) in paediatric patients 2 to 17 years of age.
Therapeutic Area (MeSH)
ATC Code
A07EA06
ATC Item
budesonide
Pharmacotherapeutic Group
Antidiarrheals, intestinal antiinflammatory / antiinfective agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Budesonide | N/A | 布地奈德 |
EMA Name
Jorveza
Medicine Name
Jorveza
Aliases
N/A